Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
isifer.se

See what CB Insights has to offer

Founded Year

2001

Stage

Angel | Alive

Total Raised

$1.11M

Last Raised

$230K | 13 yrs ago

About Isifer

Developer of a treatment for improving women's fertility. The company's solution is made of ions and pharmacological substance in defined amount, whose action consists of flushing the uterine cavity and the Fallopian tubes. The flushing action is believed to remove debris and mucus and washing away cells such as macrophages that interact negatively with the fertilization process. Its anti-inflammatory effect acts on the immunological active cells in the uterus and the abdominal cavity making the cells less capable of interacting/inactivating sperms prolonging their fertilizing capacity.

Isifer Headquarter Location

Finlandsgatan 18

Kista, 164 74,

Sweden

46 8 444 5405

Latest Isifer News

StockCall Scrutinizes Warner Chilcott, Dynavax Technologies, Isis Pharma, and United Therapeutics

Apr 11, 2013

Apr 11, 2013, 08:00 ET from StockCall.com LONDON, April 11, 2013 /PRNewswire/ -- Markets continued their bullish streak for the week and created new highs. Both S&P 500 and The Dow Jones Index closed at record highs of 1,587.73 and 14,802.24 respectively. The markets showed across the board gains with more than 75 percent of the NASDAQ stocks increased their value during the session. We followed the Healthcare sector, more precisely the Drug Manufacturers - Other industry, by tracking major companies like Warner Chilcott Plc (NASDAQ: WCRX ), Dynavax Technologies Corporation (NASDAQ: DVAX ), ISIS Pharmaceuticals Inc. (NASDAQ: ISIS ) and United Therapeutics Corporation (NASDAQ: UTHR ). StockCall reviewed the Drug Manufacturers - Other industry and chose WCRX, DVAX, ISIS, and UTHR for its technical coverage. These free reports can be seen for free at http://www.stockcall.com/signup Warner Chilcott Plc closed its latest trading session at $13.55, down 0.04 percent from its previous close. The stock traded in the range of $13.39 and $13.77 in yesterday's session and traded 4.11 million shares. It is likely to face its first resistance level at $13.98, and upon breaching this level the stock may go up to $14.62. On the downside, Warner Chilcott may tumble to $13.30 level. The stock is quite volatile as it sports a beta of 1.03. In 2013, it gained 15.91 percent whereas in the past 52 weeks, it lost 16.31 percent of its value. The stock is in a neutral mode. Download the free research on WCRX by signing up now at http://www.StockCall.com/WCRX041113.pdf Dynavax Technologies Corporation's stock is down 13.69 percent on a YTD basis, thanks to its 1.87 percent loss in the previous trading session. The stock closed at $2.37 after trading in the range of $2.36 and $2.47. The stock shows a bearish streak and may touch $2.34 level. Its second resistance level is at $2.06. It traded 3.16 million shares during Wednesday's session, up from its average trading volume of 2.78 million. Dynavax Technologies Corporation declined 54.08 percent in the past 52 weeks but has shown some recovery in 2013. It is currently trading above its short-term moving average price of $2.23. Register for today's free analysis on DVAX at http://www.StockCall.com/DVAX041113.pdf ISIS Pharmaceuticals Inc.'s stock remained in the green for its YTD returned with 4.33 percent gain in Wednesday's trading session. The stock traded in the range of $17.58 and $18.41 and closed at $18.30. However, it traded a lower-than-average number of shares at 1.12 million. The stock is in a bullish mode and is likely to maintain its upward ascent in the coming sessions. Its first resistance level is at $18.77 and it may test the support level of $18.00 in the coming trading sessions. ISIS Pharma is a fairly neutral stock with its beta at 1.08. Free report on ISIS can be accessed by registering at http://www.StockCall.com/ISIS041113.pdf United Therapeutics Corporation traded in the range of $59.87 and $61.62 in its latest trading session and ended the day at $61.26, up 2.72 percent. The stock's 52 weeks range stands at $40.34 and $63.11. The company has gained 37.05 percent of its value in the past 12 months, while it grew 17.49 percent on a YTD basis. United Therapeutics Corporation is in a bullish mode and may find its first support level at $59.33. It is trading above its 20-day moving average of $60.83, further confirming the bullish trend. United Therapeutics commands market capitalization of $3.07 billion. Register with StockCall and download the research on UTHR for free at http://www.StockCall.com/UTHR041113.pdf About StockCall.com StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Isifer Patents

Isifer has filed 2 patents.

The 3 most popular patent topics include:

  • Fertility
  • Fertility medicine
  • Gynaecology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/13/2011

12/26/2017

Clusters of differentiation, Cytokines, Monoclonal antibodies, Chemokine receptors, Immune system

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/13/2011

00/00/0000

Grant Date

12/26/2017

00/00/0000

Title

Subscribe to see more

Related Topics

Clusters of differentiation, Cytokines, Monoclonal antibodies, Chemokine receptors, Immune system

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.